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 Abstract 
Purpose: ​To apply propensity score matching to compare Baerveldt glaucoma drainage implants (BGI) to 
trabectome-mediated ab interno trabeculectomy (AIT). Recent data suggests that AIT can produce results 
similar to BGI which is traditionally reserved for more severe glaucoma.  
Methods:​ BGI and AIT patients with at least one year of follow-up were included. The primary outcome 
measures were intraocular pressure (IOP), number of glaucoma medications, and a Glaucoma Index (GI) 
score. GI reflected glaucoma severity based on visual field, the number of preoperative medications, and 
preoperative IOP. Score matching used a genetic algorithm consisting of age, gender, type of glaucoma, 
concurrent phacoemulsification, baseline number of medications, and baseline IOP. Patients with 
neovascular glaucoma, with prior glaucoma surgery or without a close match were excluded.  
Results:​ Of 353 patients, 30 AIT patients were matched to 29 BGI patients. Baseline characteristics 
including, IOP, the number of glaucoma medications, type of glaucoma , the degree of VF loss and GI were 
not significantly different between AIT and BGI. BGI had a preoperative IOP of 21.6±6.3 mmHg compared to 
21.5±7.4 for AIT on 2.8±1.1 medications and 2.5±2.3, respectively. At 30 months, the mean IOP was 
15.0±3.9 mmHg for AIT versus 15.0±5.7 mmHg for BGI (p>0.05), while the number of drops was 1.5±1.3 for 
AIT (change: p=0.001) versus 2.4±1.2 for BGI (change: p=0.17; AIT vs BGI: 0.007). Success, defined as 
IOP<21 mmHg, <20% reduction and no reoperation, was achieved at 1 year in 56% of AIT versus 55% of BGI 
(p>0.05) and 50% versus 52% at 2.5 years.  
Conclusions: ​A propensity score matched comparison of AIT and BGI demonstrated a similar IOP reduction 
through one year. AIT required fewer medications.  
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 Introduction 
The non-valved Baerveldt glaucoma implant (BGI; Abbott Medical Optics, Abbott Park, IL, USA) was 
introduced in 1990 ​[1]​ and is one of the more commonly used implants in moderate to severe glaucoma 
[2]​. The BGI allows aqueous humor in the anterior chamber to bypass the conventional outflow system into 
a subconjunctival space maintained by the barium-impregnated, silicone rubber plate of the implant ​[3]​. 
The BGI is more effective than the valved Ahmed glaucoma implant (AGI) in achieving a lower failure rate 
and a lower IOP on fewer medications than AGIs at the expense of a higher risk of hypotony ​[4]​.  
We had recently performed a comparison of AGIs to Trabectome (Neomedix, Tustin, CA, USA) ab 
interno trabeculectomies (AIT) by applying propensity score matching to achieve equivalent baseline 
conditions in both ​[5]​. Although AIT is a microincisional glaucoma surgery that uses plasma to molecularize 
and aspirate the trabecular meshwork thereby enhancing conventional outflow, our study showed a 
surprisingly similar IOP reduction that was achieved with fewer medications and fewer complications. In 
another analysis, we stratified AIT outcomes by glaucoma severity and found that a larger IOP and 
medication decrease can be achieved in more severe glaucoma ​[6–8]​. Other investigators have used AIT 
after failed glaucoma drainage implants ​[9]​ or failed trabeculectomy ​[10,11]​ reflecting these observations. 
In the present study, we propensity score matched cases of primary BGI and AIT’s to directly 
compare a large and highly effective epibulbar drainage implant to microsurgical trabecular ablation since 
the traditional indications are too different to allow for prospective randomization.  
 
Methods 
This retrospective analysis was approved by the Institutional Review Board of the University of Pittsburgh  
(PRO14100026) ​ in accordance with the Declaration of Helsinki and the Health Insurance Portability and 
Accountability Act. No consent was required due to the retrospective nature of the study. We 
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 retrospectively reviewed the medical records of patients who underwent BGI or AIT between March of 
2012 through August of 2014, were over 18 years old and with or without phacoemulsification. Patients 
with neovascular glaucoma or prior glaucoma surgery were excluded. 
The cohorts were compared using propensity-score case matching using a genetic algorithm based 
on age, gender, type of glaucoma, concurrent phacoemulsification, and baseline IOP ​[12,13]​. Cases of AIT 
or BGI too different from their counterparts were excluded. The main outcome measure was the mean IOP 
reduction. Secondary measures were reduction of medications and failure rates. Failure (using criteria of 
the Tube versus Trabeculectomy trial) ​[14]​ was defined as any one of IOP < 6, IOP > 21, or a smaller than 
20% decrease from baseline at any two consecutive visits after the 90 day immediate postoperative period, 
or the need for a subsequent glaucoma procedure. 
Surgical Technique 
Procedures were performed by the same group of surgeons on comparable patient populations for 
primary and secondary open angle glaucomas and chronic angle closure. AIT was done before 
phacoemulsification in combined cases. Approximately 140-160 degrees of nasal TM was ablated under 
direct gonioscopic view. BGI’s were inserted through a fornix-based conjunctival flap in the superotemporal 
quadrant when possible (92% of cases). The tube was positioned on the anterior surface of the iris. All 
patients received topical fluoroquinolone and prednisolone acetate 1% four times daily. AIT patients were 
also given pilocarpine 2% four times daily for 1 month then twice daily for one month. All preoperative 
glaucoma medications were stopped on the day of surgery and then added back at the discretion of the 
surgeon. Postoperative visits at day 1, week 1, month 1, month 3, month 6, month 12, month 18, month 24 
and month 30 were analyzed. 
Statistics 
Cases were matched with propensity scores (package “Matching” in R) ​[15,16]​ using a genetic 
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 algorithm based on age, gender, type of glaucoma, concurrent phacoemulsification, baseline IOP and 
medications. Cases of AIT or BGI too different from their counterparts were excluded. Weighted linear 
regression was significant when p<0.05. A Kaplan-Meier survival curve for right-censored data with 80% 
confidence intervals was computed. A Cox proportional hazard model was developed to estimate the 
effects of preoperative IOP on surgical success. 
Results 
A total of 353 patients met the inclusion criteria. Two hundred and fifty seven eyes were excluded for the 
occurrence of concurrent surgeries or short follow up. Of the 257 eyes that were excluded, 178 were from 
the AIT group and 79 were from the BGI group. After propensity score matching 37 eyes from the AIT group 
and three eyes from the BGI group were excluded. The final cohort included 30 AIT’s and 29 BGI’s of 59 
patients ​(Fig 1)​. Using weighted means, there was no significant difference between the two groups for any 
of the demographic variables measured including age, gender, type of glaucoma, baseline IOP and the 
number of medications (all p>0.05) ​(Table 1)​.  
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Fig 1. Baerveldt glaucoma drainage implant (BGI) and Trabectome-mediated ab interno trabeculectomy. 
The BGI (left and center (red)) is most commonly inserted under the superior and lateral recti muscles. AIT 
is performed along the nasal angle (temporal ablation with nasal incision depicted in this illustration). The 
tip of the trabectome has a protective footplate that feeds the trabecular meshwork towards the active and 
passive electrode where plasma is generated (top right). The molecularized tissue is removed by aspiration 
and irrigation. 
 
Table 1.​ Weighed Baseline Demographics with ab interno trabeculectomy (AIT) versus Baerveldt Glaucoma 
Implant (BGI). SD: standard deviation. 
 BGI 
mean±SD 
AIT 
mean±SD) 
p-value 
n 29 30  
Age, years old (range) 69.1±11.6 68.3±12.5 0.83 
Female, % 46.4 44.6 0.91 
Type of glaucoma   0.56 
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 POAG, % 71.4 76.8  
CACG, % 10.7 10.7  
Pigmentary, % 7.14 3.57  
Other glaucoma, % 10.7 8.93  
Cases with phacoemulsification, (%) 53.6 53.6 1.00 
Baseline IOP (mmHg) 21.6±6.3 21.5±7.4 0.95 
Baseline # Medications 2.7±1.2 2.5±1.8 0.57 
 
Both groups started at a statistically similar IOP of 21.6±6.3 for BGI and 21.5±7.4 mmHg for AIT, 
p=0.95 ​(Fig 2)​. After 2.5 years, the IOP for BGI and AIT decreased to  15.0±5.7 mmHg and 15.0±3.9 mmHg 
(p=0.43), respectively.  
 
Fig 2. IOP of patients with BGI and AIT. ​Intraocular pressures (IOP) in Baerveldt glaucoma drainage 
implants (BGI) and Trabectome ab interno trabeculectomies (AIT) were similar during the time under study. 
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 As with IOP, there were no statistically significant differences in medication use. The BGI group 
averaged ​2.8±1.1 ​ medications at baseline and 2.4±1.2 at 2.5 years (p=0.17) ​(Fig 3)​. The AIT group averaged 
2.3±1.2 ​medications at baseline, which decreased to 1.5±1.3 years (change: p=0.001; AIT vs BGI: 0.007). 
 
Fig 3. Glaucoma medications in BGI and AIT. ​in Baerveldt glaucoma drainage implants (BGI) and 
Trabectome ab interno trabeculectomies (AIT) were similar during the time under study. 
 
Failure was defined as any one of IOP < 6, IOP > 21, or a smaller than 20% decrease from baseline at 
any two consecutive visits after the 90 day immediate postoperative period, or the need for a subsequent 
glaucoma procedure. ​Success, defined as IOP<21 mmHg, <20% reduction and no reoperation, was achieved 
in 56% of AIT versus 55% of BGI at 1 year (p>0.05) and 50% versus 52% at 2.5 years ​(Fig 4)​. 
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Fig 4. Kaplan Meier Survival of BGI and AIT. ​ Performance of Baerveldt glaucoma drainage implants (BGI) 
and ab interno trabeculectomy (AIT) was similar in patients matched preoperatively. 
 
When we modeled survival with a Cox hazard model and a preoperative IOP variable of 16 mmHg, 
approximately about 40% survived at 1 year before stabilizing at 30% ​(Fig 5)​. There was no difference 
between the two groups. When the IOP variable was increased to 21 mmHg, a stable survival of 50% was 
achieved at two years both AIT and BGI. With baseline IOP set to 26 mmHg, survival was 75% at 500 days 
and onward for both groups.  
 
9 
 Fig 5.​ ​Cox Hazard modelling of BGI and AIT with a target IOP of 16, 21 and 26 mmHg.​ Performance of 
Baerveldt glaucoma drainage implants (BGI) and ab interno trabeculectomy (AIT) was similar in patients 
matched preoperatively.  
 
After AIT, the only complication noted was cystoid macular edema (CME) that occurred in a single 
case which was combined with phacoemulsification.  After BGI, complications included hypotony 
associated with choroidal detachment past three months (two patients), CME (one patient), conjunctival 
retraction that required surgical revision (one patient), and aqueous misdirection (one patient).  
 
Discussion 
In this study, we found that Trabectome-mediated ab interno trabeculectomy (AIT) and Baerveldt 
glaucoma drainage devices (BGI) achieved a similar IOP reduction but that BGI had a higher rate of 
complications compared to AIT. Until recently, AIT had not been directly compared to traditional glaucoma 
surgeries because the indications and performance were considered too different. Our prior study 
suggested that AIT and Ahmed glaucoma drainage devices can achieve a comparable pressure reduction 
when matched carefully on preoperative conditions ​[5]​.  
AIT enhances the normal, conventional outflow by removing the trabecular meshwork that 
constitutes the majority of outflow resistance ​[17,18]​. In contrast, epibulbar glaucoma drainage implants 
bypass both the conventional and the uveoscleral route entirely but are subject to encapsidation that is the 
result of fibrosis and a chronic foreign body reaction ​[19]​. We recently expanded our practice pattern to 
use AIT as a first surgery for more than mild glaucoma because our studies suggested that AIT can be used 
after failed trabeculectomy ​[10]​, in narrow angles ​[20]​ and for more severe glaucoma ​[6–8]​. BGIs lowered 
IOP to a similar extend as trabeculectomies in a randomized controlled trial but had a higher success rate 
[14]​. In the present study the success rates are relatively similar.  
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 This study has several limitations, starting with a relatively small number of patients caused by a 
limited recruitment window from a tertiary referral center. We excluded cases where AIT is 
contraindicated, notably active neovascular glaucoma. This could bias the results toward AIT by excluding 
the most complex cases of glaucoma where IOP reduction with AIT (but not BGI) ​[21]​ might not be possible. 
We also excluded cases with previous glaucoma surgery which may help explain the relatively high final IOP 
in the BGI group. The IOP after BGI only decreased from 21.6 to 15 mmHg. Although this is a 31% decrease, 
lower IOP’s were reached in large prospective trials such as the TVT (3 year IOP of 13.3 mmHg, a 47% 
decrease) ​[14]​, and the pooled Ahmed Baerveldt comparison (3 year IOP of 13.8 mmHg, a 57% decrease) 
[4]​. 
Conclusions 
Using propensity score matching, AIT resulted in an IOP reduction, final IOP and success rate that 
was similar to BGI. Patients who underwent AIT required fewer medications and had fewer complications. 
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